ScripBiogen was forecasting another year of sales and earnings declines in 2025 as the company resets its business away from mature multiple sclerosis drugs toward a portfolio of newer growth drivers, but
ScripGilead Sciences’ Yeytuo (lenacapavir) and Eli Lilly’s Kisunla (donanemab) are among the drugs that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for
ScripPatients with early Alzheimer’s disease, caregivers and doctors who may have been reluctant to try Eli Lilly’s Kisunla (donanemab) due to the risk of amyloid-related imaging abnormalities (ARIA) with
ScripBliss Biopharmaceutical (Hangzhou) (BlissBio), a Chinese developer of antibody-drug conjugates (ADCs), will rely on itself to advance BB-1701, a HER2-targeting ADC carrying the microtubule inhibitor e